FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Won approval for a new prostate cancer diagnostic and started the Korean Phase 3 trial of its therapy candidate FC705.

  • Began dosing the first patient in the Korean FC705 Phase 3 trial. Source
  • Prostaview Injection received Korean new-drug approval. Source

Roles often seen at this stageClinical & PV · Regulatory affairs · Manufacturing & MSAT

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

FutureChem

A radiopharmaceutical company with diagnostic agents for lung cancer (FLT), Parkinson's disease (PDview), Alzheimer's disease (Alzavue) and prostate cancer (Prostaview), and the prostate cancer therapy candidate FC705.

Prostaview (FC303, [18F]florastamin)

Approved

A PSMA-targeted PET diagnostic for prostate cancer, approved in April 2026 as Korea's 43rd new drug, with a positive predictive value of 86.96% in Phase 3.

FC705

Phase 3

A radiopharmaceutical candidate for metastatic castration-resistant prostate cancer in a 114-patient Phase 3 trial at eight Korean hospitals.

Alzavue

Approved

A PET radiopharmaceutical for diagnosing Alzheimer's disease.

Completion reported

Received Korean approval for the FC705 Phase 3 trial plan.

Completion reported

Dosed the first patient in the Korean FC705 Phase 3 trial at Seoul St. Mary's Hospital.

Completion reported

The prostate cancer diagnostic Prostaview Injection received new-drug approval from Korea's Ministry of Food and Drug Safety.

Official role guide

FutureChem careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 4

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 퓨쳐켐, 전립선암 진단 신약 '프로스타뷰' 식약처 허가...국내 43호 신약 ↗하이뉴스 · Published 2026-05-04 · Sources checked 2026-11-18 · Original unavailable
  2. [허가/임상] 퓨쳐켐, 전립선암 방사성 신약 후보 'FC705' 3상 승인 ↗히트뉴스 · Published 2025-09-08 · Sources checked 2026-11-18 · Original unavailable
  3. 퓨쳐켐, 전립선암 진단 방사성의약품 '프로스타뷰주사액' 국내 신약 허가 승인 ↗더바이오 · Published 2026-05-04 · Sources checked 2026-11-18 · Original unavailable
  4. 퓨쳐켐, 전립선암 방사성의약품 'FC705' 국내 3상 임상 개시 ↗히트뉴스 · Published 2026-02-05 · Sources checked 2026-11-18 · Original unavailable